Delivery Order SPE2DB24D3014-SPE2DB25FKUHN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,644.71 to AmerisourceBergen Drug Corp for the supply of Myfembree (a combination oral contraceptive containing 40 mg, 1 mg, and 0.5 mg tablets in a 28-tablet package). This firm fixed price delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive award placed under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The...
- The Defense Logistics Agency awarded a delivery order valued at $2,597.46 to AmerisourceBergen Drug Corp for MYFEMBREE pharmaceutical products (40 mg, 1 mg, and 0.5 mg tablets in a 28-count package). This firm fixed-price, non-set-aside contract was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $7,220.88 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Myfembree (elagolix/estradiol/norethindrone acetate) tablets in multiple dosage strengths (40 mg, 1 mg, and 0.5 mg formulations) in a 28-tablet package. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation, with performance to be completed by August 14, 2025, and fulfillment occurring at the vendor's Conshohocken,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of pharmaceutical products. The contract, valued at $3,975.04, is for the delivery of MYFEMBREE 40 MG-1 MG-0.5 MG tablets in quantities of 28 per package, with an ultimate completion date of October 15, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
- This is a delivery order award under a Defense Logistics Agency (DLA) Indefinite Delivery Contract (IDC) held by AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award, valued at $1,584.06, is for the medical product MYFEMBREE 40 MG-1 MG-0.5 MG Tablets 28S. The contract does not have a set-aside designation, indicating it was competitively awarded. AmerisourceBergen's DLA IDC, valued at $999,999,999 and running through November 2026, serves as a primary vehicle for...
- This is a $1,566.91 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, which has no set-aside designation, is for the supply of the medication MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S, a pharmaceutical product, with a ceiling value of $1,607.13 and a period of performance ending on July 7, 2025. The contract is a firm fixed price delivery order with no set-aside designation, indicating open competition....
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $5,566.86, is for the supply of the drug MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S. It is a firm fixed-price delivery order contract with an ultimate completion date of April 1, 2025. The contract is not set-aside and is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,345.79 firm fixed-price delivery order contract, with a completion date of January 8, 2025, is for the supply of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S, a pharmaceutical product. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the...
- This federal contract award, valued at $1,557.13, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S pharmaceutical products. The contract, which runs until January 8, 2025, is a firm fixed price delivery order with no set-aside designation, indicating open competition. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, holds a significant Indefinite Delivery Contract (IDC)...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUHNDelivery Order
This delivery order, valued at $3,159.63, represents a competitively awarded, non-set-aside contract issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Myfembree (a combination oral contraceptive containing 40 mg, 1 mg, and 0.5 mg tablets in a 28-count package). The award was made on August 13, 2025, with an ultimate completion date of August 14, 2025, and reflects the firm fixed pricing structure typical of DLA pharmaceutical procurement. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a prime contract vehicle valued at $999,999,999.00 and extending through December 2026, which enables comprehensive global pharmaceutical support across the military healthcare system. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving critical federal medical procurement needs, particularly for military and veteran healthcare systems. As a prime contractor under the DLA's Pharmaceutical Prime Vendor Global Program, the company maintains the capability to supply a broad range of pharmaceutical products and medical supplies to support Defense Health Agency operations and other government healthcare systems worldwide. The company's consistent track record of competitively awarded delivery orders across multiple therapeutic domains demonstrates its established capability to meet federal procurement requirements for pharmaceutical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 8/13/25 |